CEO SUMMARY: Some executives at pharmacogenetic testing companies are criticizing the federal Food and Drug Administration for its recent actions to exercise oversight over PGx testing. But there is more to the story, said one expert who is a past adviser to the FDA on clinical laboratory testing. One issue is how to educate physicians […]
Concerns Raised Over Pharmacogenetic Tests
Two issues include lack of training for doctors to order and interpret tests correctly and fraud
- By Joseph Burns
- > From the Volume XXVI No. 12 - September 3, 2019 Issue
- Tags: clinical lab, clinical lab tests, Clinical Laboratory, Diagnostic tests, diagnostics industry, fda ldt, genetic test, lab industry, lab testing, lab tests, laboratories, ldt, Medicare, pathologists, pgx labs, pharmacogenetic, pharmacogenetic testing companies, pharmacogenetics, the clinical laboratory
